This week in drug discovery (12-16 May)
News round-up for 12-16 May by DDW Senior Digital Content Editor Diana Spencer.
Our news highlights this time focus on two major regulatory agencies, in a week that saw the European Commission (EC) launch a new fund designed to tempt US researchers to EU countries, and the US Food and Drugs Administration (FDA) roll out extensive new AI systems.
The top stories:
EC urges researchers to “choose Europe for science”
European Commission President Ursula von der Leyen has announced new funding ‘super grants’ at the ‘Choose Europe for Science’ conference.
FDA announces aggressive agency-wide AI rollout timeline
The US Food and Drug Administration (FDA) has announced an aggressive timeline to scale use of artificial intelligence (AI) internally across all FDA centres by 30 June 2025, following the completion of a new generative AI pilot for scientific reviewers.
Approvals granted for the treatment of Fragile X Syndrome
Kaerus Bioscience’s lead candidate KER-0193 has been granted both Orphan Drug Designation and Rare Pediatric Drug Designations for the treatment of Fragile X syndrome (FXS) by the US Food and Drugs Administration (FDA).
New EU approval for Johnson & Johnson’s guselkumab
The European Commission (EC) has approved Tremfya (guselkumab), the first dual-acting IL-23 inhibitor offering both subcutaneous (SC) and intravenous (IV) induction options, for adult patients with moderately to severely active Crohn’s disease.
European Commission approves Tevimbra for small cell lung cancer
The European Commission has approved Tevimbra (tislelizumab), in combination with etoposide and platinum chemotherapy, as a first-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC).
